Compare Stocks: AARD, OVID, RLMD, and CGC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.73 -3.7%	$6.32	$3.35 ▼ $17.94	$130.21M	3.74	121,692 shs	89,273 shs
CGC Canopy Growth	$0.97 +0.5%	$0.97	$0.84 ▼ $2.38	$434.97M	0.83	4.14 million shs	1.71 million shs
OVID Ovid Therapeutics	$2.78 +2.6%	$2.61	$1.12 ▼ $3.11	$529.26M	0.24	1.46 million shs	1.36 million shs
RLMD Relmada Therapeutics	$4.37 -3.7%	$5.34	$1.13 ▼ $8.00	$484.28M	0.45	1.09 million shs	847,506 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-3.70%	-13.44%	-21.18%	+55.71%	-29.95%
CGC Canopy Growth	+0.50%	-3.67%	+4.47%	-5.54%	-30.51%
OVID Ovid Therapeutics	+2.58%	-5.12%	+9.45%	+15.83%	+109.02%
RLMD Relmada Therapeutics	-3.74%	-3.32%	-20.11%	-26.55%	+197.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.73 -3.7%	$6.32	$3.35 ▼ $17.94	$130.21M	3.74	121,692 shs	89,273 shs
CGC Canopy Growth	$0.97 +0.5%	$0.97	$0.84 ▼ $2.38	$434.97M	0.83	4.14 million shs	1.71 million shs
OVID Ovid Therapeutics	$2.78 +2.6%	$2.61	$1.12 ▼ $3.11	$529.26M	0.24	1.46 million shs	1.36 million shs
RLMD Relmada Therapeutics	$4.37 -3.7%	$5.34	$1.13 ▼ $8.00	$484.28M	0.45	1.09 million shs	847,506 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-3.70%	-13.44%	-21.18%	+55.71%	-29.95%
CGC Canopy Growth	+0.50%	-3.67%	+4.47%	-5.54%	-30.51%
OVID Ovid Therapeutics	+2.58%	-5.12%	+9.45%	+15.83%	+109.02%
RLMD Relmada Therapeutics	-3.74%	-3.32%	-20.11%	-26.55%	+197.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	167.60% Upside
CGC Canopy Growth	2.20	Hold	N/A	N/A
OVID Ovid Therapeutics	2.89	Moderate Buy	$5.86	110.69% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	174.60% Upside

Current Analyst Ratings Breakdown

Latest AARD, OVID, RLMD, and CGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	OVID Ovid Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/26/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$7.00 ➝ $9.00
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	OVID Ovid Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/17/2026	OVID Ovid Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$3.42 per share	N/A
CGC Canopy Growth	$251.01M	1.74	N/A	N/A	$1.11 per share	0.88
OVID Ovid Therapeutics	$7.25M	74.89	N/A	N/A	$1.07 per share	2.60
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
CGC Canopy Growth	-$190.29M	-$0.45	N/A	N/A	N/A	-65.33%	-21.91%	-14.34%	11/6/2026 (Estimated)
OVID Ovid Therapeutics	-$17.41M	-$0.31	N/A	N/A	N/A	-240.11%	-23.64%	-20.52%	11/11/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)

Latest AARD, OVID, RLMD, and CGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OVID Ovid Therapeutics	-$0.1150	-$0.08	+$0.0350	-$0.08	$0.02 million	$0.73 million
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	-$0.02	+$0.02	-$0.02	$58.21 million	$142.62 million
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A
6/15/2026	Q4 2026	CGC Canopy Growth	-$0.06	-$0.17	-$0.11	-$0.05	$53.43 million	$51.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
CGC Canopy Growth	0.31	3.04	2.39
OVID Ovid Therapeutics	0.05	12.39	12.39
RLMD Relmada Therapeutics	N/A	29.52	29.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
CGC Canopy Growth	3.33%
OVID Ovid Therapeutics	72.24%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
CGC Canopy Growth	0.35%
OVID Ovid Therapeutics	7.00%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
CGC Canopy Growth	1,128	449.30 million	447.73 million	Optionable
OVID Ovid Therapeutics	60	195.30 million	181.63 million	Optionable
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable

AARD, OVID, RLMD, and CGC Headlines

Recent News About These Companies

Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch

September 2 at 12:50 PM | tipranks.com

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

September 1 at 8:00 AM | globenewswire.com

Corient Private Wealth LP Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1 at 4:07 AM | marketbeat.com

BlackRock Inc. Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1 at 3:20 AM | marketbeat.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | zacks.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | uk.finance.yahoo.com

Jupiter Topco LLC Invests $77.32 Million in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Position in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Relmada Therapeutics, Inc. $RLMD

August 26, 2026 | marketbeat.com

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

August 25, 2026 | zacks.com

6,391,328 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Spruce Street Capital LP

August 25, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Analysts

August 17, 2026 | marketbeat.com

616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC

August 15, 2026 | marketbeat.com

Relmada (RLMD) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

August 11, 2026 | zacks.com

Equities Analysts Issue Forecasts for RLMD Q3 Earnings

August 11, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

August 8, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8% - Time to Sell?

August 7, 2026 | marketbeat.com

Relmada Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AARD, OVID, RLMD, and CGC Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.73 -0.22 (-3.70%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$5.76 +0.03 (+0.61%)

As of 04:00 AM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Canopy Growth NASDAQ:CGC

$0.97 +0.00 (+0.50%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.99 +0.02 (+1.76%)

As of 04:22 AM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Ovid Therapeutics NASDAQ:OVID

$2.78 +0.07 (+2.58%)

As of 09/3/2026 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Relmada Therapeutics NASDAQ:RLMD

$4.37 -0.17 (-3.74%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$4.38 +0.00 (+0.11%)

As of 04:12 AM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, OVID, RLMD, and CGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, OVID, RLMD, and CGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, OVID, RLMD, and CGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AARD, OVID, RLMD, and CGC Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Canopy Growth NASDAQ:CGC

Ovid Therapeutics NASDAQ:OVID

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, OVID, RLMD, and CGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, OVID, RLMD, and CGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, OVID, RLMD, and CGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AARD, OVID, RLMD, and CGC Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Canopy Growth NASDAQ:CGC

Ovid Therapeutics NASDAQ:OVID

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools